Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
APOTHEEK S. DERVEAUX from Rijkevorsel, company number BE0429921717, closed financial year 2025 with a result of € 126,268 after tax. For that financial year APOTHEEK S. DERVEAUX recorded a gross margin of € 267,607 and equity of € 122,979. Compared with financial year 2024, the result moved from € 89,445 to € 126,268. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
€ 122,979
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 126,268
▲ 41% vs 2024
Profit after tax over the fiscal year.
€ 172,877
▲ 54% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 126,200 paid out
100 % of the profit went to the shareholders, mostly to S. DERVEAUX PHARMA - CONSULTING (100 % of the shares). That is where the money ends up.
People and assets in 2025
2.1
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 119,541
▼ 2% vs 2024
€ 56,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 27,868
▼ 12% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 76,951
▲ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,463
▼ 11% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 236,464 | € 225,443 | € 237,846 | € 267,607 | ▲ 13% |
| Profit after taxes | € 115,193 | € 94,605 | € 89,445 | € 126,268 | ▲ 41% |
| Equity | € 108,361 | € 108,465 | € 122,911 | € 122,979 | |
| Total debts | € 604,151 | € 666,604 | € 668,202 | € 757,974 | ▲ 13% |
| Cash | € 263,835 | € 131,856 | € 112,548 | € 172,877 | ▲ 54% |
| Land & buildings | € 26,734 | € 22,597 | € 22,750 | € 18,151 | ▼ 20% |
| Retained profit | € 46,361 | € 46,465 | € 60,911 | € 60,979 | |
| Dividend | € 115,000 | € 94,500 | € 75,000 | € 126,200 | ▲ 68% |
| Balance sheet total | € 712,512 | € 775,070 | € 791,113 | € 880,953 | ▲ 11% |
| Employees (FTE) | 1.9 | 2.4 | 2 | 2.1 | ▲ 0.1 |
Key figures of APOTHEEK S. DERVEAUX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to APOTHEEK S. DERVEAUX?
What happened at APOTHEEK S. DERVEAUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 126,268 (▲ 41% vs 2024). Source: NBB ↗
- New establishment in Rijkevorsel. KBO
- Start of the company according to the CBE. KBO
In short
From € 115,193 profit in 2022 to € 126,268 profit in 2025.
Paid € 31,359 in corporate taxes since 2022.
Best year ever: 2025, with € 126,268 profit.
On average € 127,400 of value added per employee in 2025.
A new publication or filing at APOTHEEK S. DERVEAUX? We notify you, reason included.
Follow APOTHEEK S. DERVEAUXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of S. DERVEAUX PHARMA - CONSULTING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
APOTHEEK S. DERVEAUXBehind APOTHEEK S. DERVEAUX is S. Derveaux Pharma-Consulting Besloten vennootschap. The shares are held by S. DERVEAUX PHARMA - CONSULTING (99.6%).
Directors
According to the 2025 annual accounts
S. Derveaux Pharma-Consulting Besloten vennootschap
Director · represented by Derveaux Sylvie
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kerkdreef 20
2310 Rijkevorsel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Self-hosted
Hosting
LEASEWEB-NL-AMS-01 Netherlands, NL
Website info
Features
Security
Details
- Company number
- 0429.921.717
- VAT number
- BE 0429.921.717
- Registered office
- Kerkdreef 20, 2310 Rijkevorsel
- Names & denominations
- APOTHEEK S. DERVEAUX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 December 1986
- Peppol
- Active · Active since 28 Aug 2025
- Contact
- apotheekderveaux.be
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers